Soihtu DTx

What Soihtu DTx does

Soihtu DTx is a Finnish digital therapeutics company founded in 2023 in Espoo, Finland, that develops a single core product called Meliora — a video game-based digital therapeutic for adults with Major Depressive Disorder (MDD). Meliora is built on a proprietary Executive Functions Training (EFT) methodology that the company developed through a decade of scientific research at Aalto University and Helsinki University, and which was validated in a comprehensive large-scale clinical trial. The intervention is designed to be engaging (narrative-driven gameplay), personalized (via precision psychiatry), and complementary to existing depression treatments, with a stated clinical focus on neurocognitive impairments not addressed by current first-line therapies. The company holds exclusive commercialization rights to Meliora, granted in 2024.

The company is pre-revenue and is currently operating in the clinical evidence and regulatory clearance phase of its lifecycle. Its go-to-market motion is event-driven, anchored on securing FDA 510(k) premarket notification for the US market and building a clinician-facing evidence base through peer-reviewed publications (in journals including JMIR Serious Games and BMC Health Services Research) and academic partnerships (Aalto University, Helsinki University, Vanderbilt University). Distribution upon clearance is planned through healthcare provider networks and prescription pathways, with US expansion explicitly enabled by the company's 2026 selection to the Techstars & Northwestern Medicine Healthcare Accelerator and by lead investor Newfund's stated mandate of helping European brain-technology startups reach the US market.

The business model is structured as a prescription subscription digital therapeutic, though pricing has not been publicly disclosed. The company is funded by approximately $3.36 million raised in a September 2024 round led by Newfund (a Paris-based early-stage VC with a dedicated €60 million brain-technology fund) with Innovestor, alongside support from Business Finland. An 11-person cross-disciplinary team of serial entrepreneurs (with backgrounds spanning gaming entrepreneurship, academic professorships, clinical practice, and PhDs) executes the strategy, augmented by a world-class advisory bench spanning computational psychiatry, regulatory affairs, transformational game design, and neurocognitive DTx commercialization. The company is a founding member of the BrainTech Alliance and a member of the Digital Therapeutics Alliance and Sustainable Games Alliance, positioning it at the intersection of brain technology, evidence-based digital therapeutics, and sustainable game development.

Name

Soihtu DTx

Legal name

Soihtu DTx

Website

https://soihtudtx.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Soihtu DTx is a Finnish digital therapeutics company developing Meliora, a video game-based prescription digital therapeutic using proprietary Executive Functions Training to treat adult Major Depressive Disorder, with exclusive commercialization rights licensed from Aalto University and a planned US launch via FDA 510(k) clearance.

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Custom Computer Programming Services (541511)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Prescription Digital Therapeutics (PDT) (HLACANAB)

akta.pro secondary industry

Condition-specific Digital Therapeutics (DTx) (HLACANAA)

Keywords

• Digital therapeutics
• Depression treatment software
• Video game therapy
• Mental health technology
• Prescription digital therapeutic

Headquarters

HQ city

Espoo

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Digital Therapeutic Product: Prescription digital therapeutic for depression delivered as a video game. Revenue model not yet disclosed publicly.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Soihtu DTx develops Meliora, a personalized, precision prescription digital therapeutic delivered as a video game for adult Major Depressive Disorder (MDD). The product uses Executive Functions Training (EFT) to target neurocognitive impairments underlying depression and is validated in a large-scale clinical trial. Soihtu DTx holds exclusive commercialization rights to the Meliora intervention, which was developed over a decade of research at Aalto University.

Product overview

Soihtu DTx is a digital therapeutics company offering a single core product: Meliora. Meliora is a personalized, precision digital therapeutic delivered as a video game for depression. The intervention uses Executive Functions Training (EFT) to treat adult Major Depressive Disorder (MDD) and associated neurocognitive impairments. The product is designed to be engaging through narrative-driven gameplay while maintaining clinical validation, and is intended to seamlessly complement existing treatments. Soihtu DTx holds the exclusive commercialization rights to Meliora.

Differentiator

Problem solved

Functional benefit

Products and services

• Meliora

Quantifiable outcome

• 92% of clinical trial participants used the intervention at least once
• +3 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core, major and minor.

• Techstars & Northwestern MedicinecoreStrategic or Co-development Partner · 1 January 2026Healthcare accelerator providing three-month mentorship-driven program at Northwestern Medicine's Mansueto Innovation Institute in Chicago. Offers access to clinical expertise, healthcare networks, investors, and operational support for scaling healthcare innovation.
• Digital Therapeutics Alliance (DTA)majorStrategic or Co-development Partner · 1 March 2025Non-profit trade association founded in 2017 to advance evidence-based digital therapeutics. Membership provides access to industry leaders network and helps navigate regulatory and reimbursement landscapes.
• Sustainable Games Alliance (SGA)minorStrategic or Co-development Partner · 1 March 2025Non-profit organization committed to promoting environmental and societal responsibility in the gaming industry. Aligns with mission to integrate sustainable practices into development of game-based digital therapeutics.
• BrainTech Alliance (BTA)coreStrategic or Co-development Partner · 1 February 2025Founding member of pioneering network bringing together experts in science, venture capital, and startups to drive innovation in brain health. Founding event in February 2025 in Palo Alto brought together 60 leading academic institutions, specialized VCs, and brain-focused startups collectively managing over $2 billion in capital.
• Vanderbilt UniversityminorStrategic or Co-development PartnerAcademic research partner collaborating on neuroscience and mental health research.
• Aalto UniversitycoreStrategic or Co-development PartnerPrimary academic research partner where the Meliora intervention was developed through a decade of scientific research. Clinical trials conducted at Aalto University, Finland.
• Helsinki UniversityminorStrategic or Co-development PartnerAcademic research partner collaborating on patient studies and game-based intervention research.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Akili Interactive: Akili Interactive pioneered FDA-authorized, video game-based digital therapeutics (EndeavorRx for ADHD). As a publicly traded game-based DTx company, it is the most directly comparable peer in delivery modality (video game) and regulatory category (FDA-cleared DTx).
• Click Therapeutics: Click Therapeutics develops prescription digital therapeutics for mental health and other conditions, partnering with pharma companies. It is a direct competitor in the prescription DTx space with overlapping target indications in mental health.
• Happify Health: Happify Health offers digital mental health solutions using gamification and evidence-based interventions for depression and anxiety. It is a direct peer given overlapping target conditions (depression) and game-influenced engagement model.
• Big Health: Big Health develops prescription and consumer digital therapeutics for mental health conditions including insomnia (Sleepio) and anxiety (Daylight). It is the closest direct peer to Soihtu DTx as a fellow mental health-focused DTx pursuing prescription commercialization and payer reimbursement.

Emerging players

• BehaVR: BehaVR develops virtual reality-based digital therapeutics for mental health and chronic pain conditions. It is an emerging player in immersive technology-based DTx with overlapping target conditions and similar immersive modality to Soihtu DTx's game-based approach.
• Woebot Health: Woebot Health develops AI-chatbot-based digital therapeutic interventions for mental health, including depression. It overlaps with Soihtu DTx in DTx-for-depression category though using conversational AI rather than video game delivery.
• Limbic: Limbic is a UK-based digital mental health company offering AI-driven mental health support, including therapy referral and self-help tools used by NHS services. It is an emerging player in the European DTx-for-depression category with overlapping regulatory pathways.
• Pear Therapeutics (legacy): Pear Therapeutics pioneered prescription digital therapeutics including reSET and reSET-O for substance use disorder before bankruptcy and asset sales. Its technology and IP have been acquired, but it remains a reference point and potential acquirer-adjacent for Soihtu DTx's category.

Broad incumbents

• Headspace Health: Headspace Health (formed via Headspace/Ginger merger) provides mental health services including therapy, coaching, and digital tools to consumers and enterprises. It is a broad incumbent in digital mental health with overlapping depression treatment use cases.
• Otsuka Pharmaceutical (Digital Medicine): Otsuka developed Abilify MyCite, an FDA-approved digital medicine system pairing aripiprazole with an ingestible sensor. As a large pharma player with established FDA-cleared digital therapeutic assets, it is a broad incumbent that could be a strategic partner or acquirer for Soihtu DTx.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Soihtu DTx